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Hypertension treatment and control in sub›Saharan Africa
Figure of $1800 per life saved seems
optimistic
Editor—Cooper et al call for the inclusion
of antihypertensive treatment among health
priorities in sub›Saharan Africa.1 Assuming
that the patient needs one drug to control
his or her blood pressure and that
compliance is good, they estimate that one
death could be prevented at a cost of $1800
(£1130).
Some patients need two or more drugs
to control their hypertension, and compli›
ance rates for chronic diseases in Africa are
low for many reasons, including poverty,
lack of access to health services, mobility of
the population, and a lack of understanding
of the nature of chronic disease. In the
Republic of Congo patients arrive at a
health centre to be cured. A doctor who can
only control an illness is often seen as
having failed, and the patient will then either
try a new doctor or consult the local healer.
The Centre MØdical Evangelique runs
an externally funded project for patients
with epilepsy. The cost of the treatment is
only $18›$24 (£11.70›£15.10) a year, and
most patients see a considerable change in
their condition. The programme is mobile
to facilitate access. Despite this the average
non›attendance at any consultation is about
40%. This figure is likely to be higher for a
similar programme of antihypertensive
treatment, because the patient often experi›
ences no improvement in symptoms and
may have side effects from the medicine
prescribed.
I think that Cooper et al’s figure of
$1800 per life saved is optimistic. Even if
accurate it means that antihypertensive
treatment cannot rank alongside the provi›
sion of clean water, vaccination, and oral
rehydration in terms of lives saved per unit
cost. So what should be done for hyperten›
sion in sub›Saharan Africa? I believe we
should treat patients with symptoms or
complications, or both, as they are more
likely to be compliant with treatment. We
should also treat those who want to be
treated and who understand the importance
of continuing treatment. Doctors and other
interested parties need to disseminate infor›
mation to their communities about the
nature and risks of hypertension.
Finally, the authors do not mention the
value of dietary salt restriction. This is cheap
and particularly effective in African popula›
tions.2 Measures such as this would have a
greater impact on the prevalence of
hypertension in the African continent.
Justin Burdon Medical officer
Centre MØdical Evangelique, Nyankunde, Republic
of Congo (c/o PO Box 21285, Nairobi, Kenya)
1 Cooper RS, Rotimi CN, Kaufman JS, Muna WFT, Mensah
GA. Hypertension treatment and control in sub›Saharan
Africa: the epidemiological basis for policy. BMJ 1998;
316:614›7. (21 February.)
2 La lutte contre l’hypertension. Rapport d’un comitØ OMS
d’experts.Geneva: Organisation Mondiale de la SantØ, 1996.
(OMS; SØrie de rapports techniques No 862.)
Amount spent on health care per capita is
same as cost of a McDonald’s
Editor—Cooper et al’s article on hyperten›
sion treatment and control in sub›Saharan
Africa was another example of cultural
(medical) imperialism.1 The science is sound
and the argument reasonable, but the article
shows how out of touch academics in
learned institutions are with medicine at the
grass roots.
I ran a hospital in rural Uganda for
some years. The way in which nearly all
health care is provided in Uganda and
neighbouring countries is commercial:
health care has to be paid for. People
delivering it have to receive their income
from the patients they treat. A patient
attending a hospital or clinic has to pay a fee
for consultation, fees for investigations, and
then the cost of the drugs. The institutions
depend exclusively on this income to sustain
themselves. Even a programme supplying
free antihypertensive drugs to clinics would
not get round that problem.
The average amount of money spent per
head of population each year is about the
cost of a meal at McDonald’s, and medical
care is sought only in an emergency. How
anyone in the West could expect a peasant
farmer to spend £22 a year on a drug that
treats a disease that causes him or her no
suffering is beyond me. It is absurd to
suggest that over £1000 a year should be
spent to save one life from hypertension
when the great majority of these people
don’t have clean water to drink. The hospital
I worked in saved hundreds, if not thou›
sands, of lives, each one at a cost of a fraction
of £1000. I struggled desperately to make
ends meet and keep it going. A mere
£30 000 makes the difference between
collapse and survival.
Virtually the only section of the article
that prompts my agreement is the very last
clause: “instead . . . investment in an organ›
ised care system would reap large gains in
adult health.”
R WMontgomery General practitioner
St Luke’s Medical Centre, Brixham, Devon TQ5 8NA
1 Cooper RS, Rotimi CN, Kaufman JS, Muna WFT, Mensah
GA. Hypertension treatment and control in sub›Saharan
Africa: the epidemiological basis for policy. BMJ 1998;
316:614›7. (21 February.)
Burden of cerebrovascular disease will
increase as more people survive to old age
Editor—We agree with Cooper et al’s
conclusion that hypertension is worth treat›
ing in sub›Saharan Africa but would like to
raise two points.1 Although in developed
countries more deaths from ischaemic heart
disease than stroke are attributable to
hypertension,2 this is not true of sub›
Saharan Africa, where (particularly in rural
areas) ischaemic heart disease is rare; thus
care needs to be taken when one is compar›
ing figures in which cardiovascular diseases
are grouped together. The limited data on
stroke that exist for sub›Saharan Africa
mainly relate to hospital studies. They
suggest high rates of hypertension, and high
rates of default from treatment for hyperten›
sion, in those patients who attend hospital
with stroke.3
While knowledge of cause specific
mortality in adults in sub›Saharan Africa is
limited, so also is information about cause
specific morbidity. Cerebrovascular disease
is a major cause of disability in people who
survive stroke in developed countries.
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Although absolute numbers in sub›Saharan
Africa are currently low,4 as the proportion
of people surviving to old age increases so
will the burden of cerebrovascular disease;
age standardised mortality already exceeds
that in the United Kingdom.5 The most
important risk factor for stroke amenable to
modification is hypertension, and we are
piloting cost effective methods of control›
ling hypertension in rural and urban areas
through the “health in the next millennium”
programme of the Department for Inter›
national Development.
Richard Walker Consultant geriatrician
North Tyneside General Hospital, North Shields
NE29 8AH
N Unwin Senior lecturer in epidemiology and public
health
Medical School, University of Newcastle upon Tyne,
Newcastle upon Tyne NE1 7RU
K G M M Alberti President
Royal College of Physicians of London, London
NW1 4LE
1 Cooper RS, Rotimi CN, Kaufman JS, Muna WFT, Mensah
GA. Hypertension treatment and control in sub›Saharan
Africa: the epidemiological basis for policy. BMJ
1998;316:614›7. (21 February.)
2 Bianchi G, Swales JD. Do we need more anti›hypertensive
drugs: lessons from the new biology. Lancet 1995;345:
1555›7.
3 Walker R. Hypertension and stroke in sub›Saharan Africa.
Trans R Soc Trop Med Hyg 1994;88:609›11.
4 Walker RW, Masuki G, Kitange HM, McLarty DG.
Prevalence of stroke disability and use of services in a rural
Tanzanian population. Age Ageing 1996;25(suppl 2):9.
5 Ministry of Health. Policy implications of adult morbidity and
mortality. End of phase 1 report. Dar es Salaam: Ministry of
Health, Government of Tanzania, 1997.
Authors’ reply
Editor—We agree with Burdon that our
estimate of efficacy may not hold for all
communities. Our interest was to advance a
discussion based on evidence. For example,
while it is true that some patients will require
two or more drugs, it would be useful to
undertake studies to determine how much
risk reduction would occur with a simple
regimen of one drug versus tailored multi›
drug treatment. We also need to evaluate the
proportion of patients who will continue to
take treatment long term; this may vary
widely from one setting to the next. In the
United States, after 30 years of effort, hyper›
tension is controlled in only a quarter of
hypertensive patients; we should not aban›
don interventions in Africa because they fail
to meet an unreasonable standard.
We understand Burdon’s motivation to
restrict treatment to patients who have end
organ damage or symptoms, but we believe
that this is too late—renal failure or stroke is
often a death sentence in Africa. Further›
more, it concentrates the effort on such a
small group of patients that the investment
in the whole process has little payoff. We
cannot find any evidence for concluding that
compliance among asymptomatic hyperten›
sive patients is an overwhelming obstacle. In
our communities in Nigeria and Cameroon
a vigorous campaign to increase awareness
has resulted in many patients taking their
pills faithfully, although we cannot quantify
that effect. We are wary of authoritative
proclamations that are based on opinion
alone. Non›pharmacological interventions
have considerable appeal. Unfortunately,
they do not work for patients with severe
hypertension.
We are no more sympathetic to Mont›
gomery’s position than he is to ours. We may
sound like medical imperialists, but he
sounds like Albert Schweitzer. Presumably
he believes that Africans should not be
treated for hypertension; at the very least he
is out of touch—millions are. In Cameroon,
for example, government programmes exist
to provide care for hypertension and
diabetes. And why not? Because the patients
also need clean water? If they need
treatment, and are being treated, should we
not have a policy? Perhaps antihypertensive
treatment will be irrational in some African
settings; it may also be highly appropriate in
others. It is better to answer those questions
with data.
We appreciate the comments from
Walker et al. The group in Tanzania is mak›
ing enormous contributions to our under›
standing of chronic disease in Africa.
Richard Cooper Chairman
Department of Preventive Medicine and
Epidemiology, Loyola University Medical School,
Maywood, IL 60153, USA
Walinjom Muna Chief of cardiology
University of the Health Sciences, Yaounde,
Cameroon
For the Chronic Disease Network in the African
Diaspora
Ion channels
Ion specificity of motor end plate
acetylcholine receptor
Editor—I was surprised by the assertion of
Laniado et al that “acetylcholine. . .acts at the
postsynaptic membrane of the motor end
plate to open chloride channels.”1 In a series
of classic experiments in the 1960s,
Takeuchi and Takeuchi used glass micro›
electrodes to clamp the end plate region of
partially curarised frog sartorius muscle.2
The end plate current decreased as the
membrane potential was clamped at
increasing values from its starting value of
− 100 mV. End plate current was zero at a
membrane potential of − 15 mV (the
reversal potential). This reversal potential
was affected by changing external sodium
and potassium concentration (becoming
more positive with increasing cation con›
centrations), but it was not affected by
changing the chloride concentration. This
result suggested that the channel was
permeable to sodium and potassium but not
to chloride ions. Further studies extended
these conclusions, and the channel was
found to be permeable to calcium and mag›
nesium and organic cations (but not anions).
Indeed, the finding that the channel perme›
ability for divalent cations is somewhat less
at high cation concentrations has led to the
suggestion that there are negative charges
on the external surface near the mouth of
the channel.3
Other studies analysing the reversal
potential have shown that chloride channels
are associated with ã›aminobutyric acid
receptors4 and glycine activated channels.5 I
am not, however, aware of studies showing
that the action of acetylcholine at the motor
end plate opens chloride channels, either in
mammals or in other species.
Jaideep J Pandit Lecturer in medicine
St Hugh’s College, Oxford OX2 6LE
1 Laniado ME, Abel PD, Lalani E›N. Ion channels. BMJ
1997;315:1171›2. (8 November.)
2 Takeuchi A, Takeuchi N. On the permeability of the
end›plate membrane during the action of the transmitter.
J Physiol (Lond) 1960;154:52›67.
3 Dwyer TM, Adams DJ, Hille B. The permeability of the
endplate channel to organic cations in frog muscle. J Gen
Physiol 1980;75: 469›92.
4 Takeuchi A, Takeuchi N. Localised action of gamma›amino
butyric acid on the crayfish muscle. J Physiol (Lond)
1965;177:225›38.
5 Bormann J, Hamill OP, Sakmann B. Mechanism of anion
permeation through channels gated by glycine and
ã›amino butyric acid in mouse cultured spinal neurones.
J Physiol (Lond) 1987;385:243›86.
Authors’ reply
Editor—Pandit has drawn attention to the
action of acetylcholine and ion channels in
relation to the motor end plate. Acetylcho›
line can result in the opening of chloride
channels in other locations, and we acknowl›
edge him for providing a succinct explana›
tion of their relation.1 2
Marc E Laniado Clinical research fellow in urology
Paul D Abel Reader in urology
El›Nasir Lalani Senior lecturer in histopathology
Hammersmith Hospital, London W12 ONN
1 Ikeda K, Wu D, Takasaka T. Inhibition of acetylcholine›
evoked Cl − currents by 14›membered macrolide antibiot›
ics in isolated acinar cells of the guinea pig nasal gland.Am
J Respir Cell Mol Biol 1995;13:449›54.
2 Arellano RO, Miledi R. Novel Cl − currents elicited by folli›
cle stimulating hormone and acetylcholine in follicle›
enclosed Xenopus oocytes. J Gen Physiol 1993;102:833›57.
Mistaken subdural cannulation
can produce Horner’s
syndrome
Editor—Minerva showed a photograph of
a patient with Horner’s syndrome after a
supposed epidural infusion.1 I have seen a
similar presentation after insertion of what I
had presumed to be an epidural catheter.
However, with the development of unilateral
Horner’s syndrome and a high patchy block
with sacral sparing it became apparent that
the catheter was in fact in the subdural
space. Subdural cannulation is said to occur
in 0.1›0.8% of all epidurals and is often
missed.2
I suspect that this is what happened to
Paw’s patient. The risk of rupture of the deli›
cate arachnoid matter resulting in total
spinal anaesthesia makes it mandatory to
remove and resite the catheter in the
epidural space.
Ian Makkison Specialist registrar
Department of Anaesthetics, Queens Medical
Centre, Nottingham NG7 2UH
1 Paw H. Minerva. BMJ 1998;316:160. (10 January.)
2 Datta S. The obstetric anesthesia handbook 1995. 2nd ed. St
Louis: Mosby, 1995:134.
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Incorporating patient
preferences into clinical trials
Information about patients’ preference
must be obtained first
Editor—Torgerson and Sibbald discuss the
difficulties of assessing the relative merits of
treatments when patients have strong
preferences for one of the alternatives.1 In
these circumstances, however, patients
should not be expected to participate in
randomised comparisons, and neither
should the professionals caring for them.
It is important to consider the bases of
these preferences, particularly as there is a
widespread and unsupported belief that
new treatments are likely to be superior to
existing alternatives.2 For example, it seems
that people with diabetes who were being
recruited to a randomised comparison of
insulin pumps with conventional manage›
ment were left with the impression that
pumps represented an important advance
(C Bradley, personal communication). Not
surprisingly, therefore, those allocated to
pumps were pleased, while those allocated
to conventional management were disap›
pointed. Randomisation thus created com›
parison groups that were incomparable in
these psychological characteristics, and this
may have had implications for compliance
and evaluation of treatment outcome.3
Bradley’s response3 was to propose the
partially randomised patient preference
design to which Torgerson and Sibbald
refer. Unfortunately, this does not help
because it cannot distinguish between an
effect of preferences and an effect of
confounding of preferences with prognosis.
Since it is impossible to randomise between
sincerely held preferences, measuring their
effects reliably requires a more complicated
design, which was suggested originally by
Rucker4 and recently discussed by McPher›
son et al.5 In this design, people are
randomised between either a randomised
comparison or a preference comparison.
Genuine therapeutic effects may, how›
ever, be associated with preferences, over
and above those related to adherence to
treatment. Several blind trials show an
advantage associated with adherence to pla›
cebo.5 Obtaining hard evidence on possible
preference effects is problematic as it is diffi›
cult to distinguish reliably between simple
therapeutic effects and preference effects
mediated through psychological pathways
in experiments.
There are thus two areas that need
attention. Firstly, there needs to be wider
acknowledgement that preferences for treat›
ments should be based on beliefs that are
founded on reliable information. This
should help to increase the proportion of
well informed people who have no strong
preferences and would thus be eligible to
participate in comparisons between ran›
domised treatments. Secondly, studies are
required to enable a rigorous distinction to
be made between simple therapeutic effects
and preference effects. This means that well
accepted biological hypotheses will be
needed for adequate recruitment, and a
plausible biological model to distinguish the
two kinds of effect. As Torgerson and
Sibbald suggest, however, the first step is
routinely to elicit information about the
preferences of well informed patients.
Klim McPherson Professor of public health
epidemiology
Department of Public Health and Policy, London
School of Hygiene and Tropical Medicine, London
WC1E 7HT
Iain Chalmers Director
UK Cochrane Centre, Oxford OX2 7LG
1 Torgerson DJ, Sibbald B. What is a patient preference trial?
BMJ 1998;316:360. (31 January.)
2 Chalmers I. What is the prior probability of proposed new
treatment being superior to an established treatment? BMJ
1997;314:74›5.
3 Bradley C. Clinical trials—time for a paradigm shift? Diabet
Med 1988;5:107›9.
4 Rucker G. A two›stage trials design for testing treatment,
self›selection and treatment preference effects. Stat Med
1989;8:477›85.
5 McPherson K, Britton A, Wennberg JE. Are randomised
controlled trials controlled? Patient preferences and
unblind trials. J R Soc Med 1997;90:652›56.
Merits of alternative strategies for
incorporating patient preferences into
clinical trials must be considered
carefully
Editor—In their overview of patient prefer›
ence trials, Torgerson and Sibbald suggest
that, given the potential drawbacks of such
designs, research might usefully take the
alternative approach of measuring patient
preferences within a traditional randomised
controlled trials design.1 This would con›
serve “the advantages of a fully randomised
design with the additional benefit of
allowing for the interaction between prefer›
ence and outcome to be assessed.” We used
Torgerson and Sibbald’s approach to com›
pare two schedules of routine antenatal
visits.2 Our unpublished findings on patient
preferences show how such analysis can
extend and clarify trial findings.
We stratified our two groups—new style
care (6›7 antenatal visits) and traditional
care (13 antenatal visits)—by the initial pref›
erences of the women who took part. Within
each stratum we compared those allocated
to traditional and new style care for one key
acceptability outcome (dissatisfaction with
the frequency of antenatal visits) and one
key outcome relating to psychosocial effec›
tiveness (negative attitude to the fetus). The
findings are shown in the table.
Our main overall finding of greater
dissatisfaction in the new style group applies
only to those who had either an initial pref›
erence for traditional care or no initial pref›
erence. When women had an initial prefer›
ence for new style care the effect was in the
opposite direction. Similarly, the finding that
women in the new style group had a more
negative attitude to their fetuses only applies
to those who initially preferred traditional
care or had no initial preference. This analy›
sis provides information that is relevant for
new policies: women with an active prefer›
ence for fewer visits should not be denied
this option because of concern about possi›
ble detrimental psychosocial effects.
A partially randomised patient prefer›
ence design would have yielded similar find›
ings, but at the cost of a substantial increase
in sample size. We assumed that all those
with an initial preference would have opted
for their preferred type of care and that eli›
gible women who declined participation
because they did not want to have fewer
antenatal visits would have taken part if it
had been a preference trial. We calculate that
the required overall sample size would have
increased from 2830 to 7989. This high›
lights the need to consider carefully the
respective merits of alternative strategies for
incorporating patient preferences into clini›
cal trials.
Sarah Clement Lecturer
Jim Sikorski Research fellow
Jennifer Wilson Research midwife
Bridget Candy Research associate
Department of General Practice, United Medical
and Dental Schools of Guy’s and St Thomas’s
Hospitals, London SE11 6SP
1 Torgerson DJ, Sibbald B. What is a patient preference trial?
BMJ 1998;316:360. (31 January.)
2 Sikorski J, Wilson J, Clement S, Das S, Smeeton N. A
randomised controlled trial comparing two schedules of
antenatal visits: the antenatal care project. BMJ 1996;
312:546›53.
Authors’ reply
Editor—McPherson and Chalmers are cor›
rect that more research is required into the
interaction between preferences and out›
come. Indeed, the first randomised trial
comparing an ordinary randomised trial
and a patient preference trial has just been
published.1 This trial showed no difference
in recruitment and retention rates between
the two randomised segments of the trials.
Comparison of two groups of women for one key acceptability outcome (dissatisfaction with frequency
of antenatal visits) and one key outcome relating to psychosocial effectiveness (negative attitude to
fetus)
Initial preference Allocated to traditional care Allocated to new style care Odds ratio (95% CI)*
Dissatisfaction with frequency of visits (%)
None 7.4 (29/391) 31.0 (135/435) 5.62 (3.61 to 8.94)
Traditional care 3.5 (11/317) 71.1 (118/166) 68.39 (33.31 to 149.14)
New style care 48.9 (110/225) 12.2 (36/294) 0.15 (0.01 to 0.23)
Negative attitude to fetus (mean (SD))
None 6.0 (4.25) 6.8 (4.26) 0.003
Traditional care 6.3 (4.05) 7.5 (3.83) 0.005
New style care 5.7 (4.12) 5.8 (3.77) 0.452
*P value for negative attitude to fetus.
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Clearly it is important that patients are
given reliable information. It is, however,
likely that some patients have preferences
and are still prepared to be randomised.
What should be done with such patients?
Including them in a “partially randomised
preference trial” is unsatisfactory, as
McPherson and Chalmers state. Randomis›
ing patients between a fully randomised
design and a preference trial is problematic,
as suggested, not least because those
patients allocated to a fully randomised
design must be denied their preferences if
full assessment of preferences is to be taken
into account. This is probably ethical if the
preferred treatment is available only to ran›
domised patients.
Randomising all consenting patients and
eliciting their treatment preferences may
help.2 Clement et al show that this is both fea›
sible and a better alternative to the partially
randomised design. They are, however, incor›
rect to assume that a partially randomised
patient preference trial would have yielded
similar findings. The preference arms in a
preference trial could have been subject to
confounding and, furthermore, would not
have yielded information on the dissatisfac›
tion rates and attitude scores of women
allocated to their unpreferred treatment.
The importance of this is illustrated in
the findings of their previous paper. The
odds ratio of dissatisfaction was 2.50 (95%
confidence interval 2.00 to 3.11) for the new
group compared with the traditional group.3
When all women with an initial preference
are removed (hence achieving a balance of
preference between the two groups) the
odds ratio increases to 5.62 (3.61 to 8.94),
thus indicating a significant effect of
preference on this trial outcome.
McPherson et al point out the sample
size required to test for any interaction
between preference and outcome would
need to be relatively large.4 Many trials may
be too small to examine the interaction
between preference and outcome. One solu›
tion may be to try to standardise how prefer›
ences are elicited and then use meta›
analytical techniques by combining a
number of trials to assess differences in out›
come by preference.
David J Torgerson Senior research fellow
Centre for Health Economics and Department of
Health Studies, University of York, York YO10 5DD
Bonnie Sibbald Professor
National Primary Care Research and Development
Centre, University of Manchester, Manchester
M13 9PL
1 Cooper KG, Grant AM, Garratt AM. The impact of using a
partially randomised patient preference design when
evaluating alternative managements for heavy menstrual
bleeding. Br J Obs Gynaecol 1997;104:1367›73.
2 Torgerson DJ, Klaber›Moffett J, Russell IT. Including
patient preferences in randomised clinical trials. J Health
Serv Res Policy. 1996;1:194›7.
3 Sikorski J, Wilson J, Clement S, Das S, Smeeton N. A
randomised controlled trial comparing two schedules of
antenatal visits: the antenatal care project. BMJ 1996;
312:546›53.
4 McPherson K, Britton AR, Wennberg JE. Are randomized
controlled trials controlled? Patient preferences and
unblind trials. J R Soc Med 1997;90:652›6.
Potential biases do not affect
results of waiting time study
Editor—Nick Black’s helpful letter1 raises
four potential biases in my study that may
affect the conclusion that fundholding
reduces waiting times.2
His first point concerned the accuracy of
my database. I have now made random
checks of patients’ details at general prac›
tices in the catchment areas of all four
providers. These confirmed the accuracy of
the database.
The second was that if the proportion of
patients of fundholders and non›
fundholders placed on the elective waiting
list differed this could cause contrasts in
waiting times. Overall, 61% of non›
fundholders’ patients and nearly 60.6% of
fundholders’ were placed on the elective
waiting list—a marginal difference. Anyway,
individual patients of fundholders still had
shorter waits regardless of whether there
was proportionally more or less of them
than patients of non›fundholders.
The significance of case mix variation is
best measured by the final mix of procedures
rather than by an age, sex, or diagnosis
profile. This is because long waits for specific
types of operations may affect waiting time
differences if the incidence of those opera›
tions is far greater in one population than the
other. Analysis by the ÷2 test for independ›
ence shows the mix of procedures to be
broadly similar, although in 11 of the 16 cases
significant differences occurred between
actual and expected activity for a few (at most
three) of the 10 most common procedures. In
five of these 11, case mix actually increased
the waits of fundholders more than non›
fundholders. In the other six, increases to the
waits of non›fundholders, relative to
fundholders, were too marginal to reverse the
original results.
The fourth doubt concerned the use of
the mean as a measure of waiting time
rather than the median. However, the analy›
sis of variance tests used to compute the sig›
nificance of differences do take account of
variances within columns (within the same
population) as well as between them. The
table shows the median waits. These confirm
the results shown by the mean with the
exception of Worthing and Southlands in
1995›6. In the other 15 cases patients of
fundholders still have appreciably shorter
waits. Therefore, my original conclusion that
fundholding reduces waiting times seems
justified.
Bernard Dowling Research student
Department of Social Policy and Administration,
London School of Economics and Political Science,
London WC2A 2AE
1 Black N. Potential biases were not taken into account in
study of waiting times. BMJ 1998;316:149. (10 January.)
2 Dowling B. Effect of fundholding on waiting times:
database study. BMJ 1997;315:290›2. (2 August.)
Temporary pacing before
permanent pacing should be
avoided unless essential
Editor—Fitchet and Fitzpatrick report a
case of air embolism resulting from a poorly
sealed temporary pacing wire,1 but they do
not discuss an important point—namely,
that insertion of a temporary pacing wire
before permanent pacing is hazardous and
should be avoided unless essential.2 Inser›
tion of a temporary wire in such circum›
stances combines the risks of central venous
access with those of systemic infection while
fouling one potential vascular access site.
At Papworth Hospital 15% of patients
admitted for permanent pacing are trans›
ferred from another hospital with a tempo›
rary pacing wire in situ.3 A considerable
proportion of these patients develop sys›
temic infection as a result, requiring
intravenous antibiotics; permanent pacing
then has to be delayed by up to a week (of
expensive in›hospital stay).3 Irrespective of
this, patients with a temporary wire have a
sixfold increased risk of infection of their
permanent pacing system.4 This outcome
can be associated with a mortality of up to
50% if infected leads are not removed5—a
procedure that itself has a 2% mortality.
The 71 year old woman in the case
reported had bifascicular block and asymp›
tomatic intermittent complete heart block.
This arrhythmia does not require temporary
pacing, and recognition of this fact would
have prevented the unfortunate conse›
quences. Patients are frequently transferred
from district hospitals to specialist centres
with unnecessary temporary pacing wires.3
We suggest that, if there is doubt, the
decision to insert a temporary system before
permanent pacing should be made in
conjunction with the specialist centre.
David J R Hildick›Smith Specialist registrar
Michael C Petch Consultant cardiologist
Papworth Hospital, Cambridge CB3 0RE
Median waits of patients of non›fundholders and
fundholders for elective operations covered by
fundholding scheme for four NHS providers over
four years
Provider and year
Non›fundholders
(days)
Fundholders
(days)
Crawley and Horsham:
1992›3 69 62
1993›4 167 65
1994›5 132 58
1995›6 168 115
Mid›Sussex:
1992›3 54 44
1993›4 62 43
1994›5 62 44.5
1995›6 59 47
Royal West Sussex:
1992›3 176 61
1993›4 245 105
1994›5 284 126
1995›6 153 65
Worthing and Southlands:
1992›3 74 48
1993›4 83 59
1994›5 80 62
1995›6 83 83
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1 Fitchet A, Fitzpatrick AP. Central venous air embolism
causing pulmonary oedema mimicking left ventricular
failure. BMJ 1998;316:604›6. (21 February.)
2 Winner S, Boon N. Clinical problems with temporary
pacemakers prior to permanent pacing. J R Coll Physicians
Lond 1979;23:161›3.
3 Chauhan A, Grace AA, Newell SA, Stone DL, Shapiro LM,
Schofield PM, et al. Early complications after dual chamber
versus single chamber pacemaker implantation. Pacing
Clin Electrophysiol 1994;17:2012›5.
4 Aggarwal RK, Connelly DT, Ray SG, Ball J, Charles RG.
Early complications of permanent pacemaker implanta›
tion: no difference between dual and single chamber
systems. Br Heart J 1995;73:571›5.
5 Rettig G, Doenecke P, Sen S. Complications with retained
transvenous pacemaker electrodes. Am Heart J 1979;98:
587›94.
People at risk of coronary heart
disease should not be denied
treatment with effective drugs
for purely financial reasons
Editor—As soon as effective treatments for
coronary heart disease—which causes 30% of
deaths in the United Kingdom—became
available, evidence based medicine and
finance clashed. The Standing Medical Advi›
sory Committee attempted to impose the
Sheffield risk tables1 and was condemned for
its simplistic guidelines and high threshold
for treatment.2 A report on cholesterol and
heart disease by the NHS Centre for Reviews
and Dissemination now seeks to reduce
expenditure on statins by focusing clinical
effort on modification of lifestyle and
treatment for mild hypertension.3
The relation between cholesterol and
coronary heart disease is log›linear so a
“normal” cholesterol concentration is a
fallacy. Most people in the United Kingdom
have high cholesterol concentrations and
would benefit from lipid lowering. To reduce
coronary heart disease in the United
Kingdom people must change their life›
styles, but evidence for the success of lifestyle
modification is depressing: participants in
the OXCHECK study reduced their
cholesterol concentrations by only 3% and
their body mass by 2%.4
The report admits that lowering
cholesterol concentrations is beneficial but
claims that statins are too expensive,
compared with treatment for hypertension
with off patent drugs. Many patients with
hypertension, however, receive multiple pat›
ented drugs at a cost similar to that of statins.
The cost of treatment of hypertension—
number needed to treat = 40 at a blood
pressure of 170/100 mm Hg—is similar to
that of primary prevention for high risk
patients with cholesterol concentrations of
7 mmol/l. The west of Scotland coronary
prevention study showed a 30% reduction in
mortality despite a 30% dropout rate.5 The
7›year extension of the Scandinavian simva›
statin survival study suggests a reduction of
47% in event rates in the treatment group.
Lipid lowering may therefore be even more
cost effective than previously believed.
Treatment with statins is more effective
than multidrug treatment for hypertension in
reducing absolute risks: a 30% reduction can
be achieved with a single drug, compared
with 10% reductions for any single antihyper›
tensive drug. Statins also have fewer side
effects. The issue of statins approaching
expiry of their patent is irrelevant. It is unethi›
cal not to treat people at risk of coronary
heart disease with effective drugs for purely
financial reasons—just as it would be unethi›
cal not to treat those who smoke or are obese.
The report leaves us little further
forward in deciding whom we should treat
or where the necessary money should come
from. Unfortunately its press release and the
subsequent media reports convey a negative
message to healthcare providers and to
those patients who need to have their lipids
measured and adequately treated.
T M Reynolds Consultant chemical pathologist
Clinical Chemistry Department, Burton Hospital,
Burton upon Trent DE13 0RB
A S Wierzbicki Senior lecturer in chemical pathology
M A Crook Consultant chemical pathologist
St Thomas’s Hospital, London SE1 7EH
N E Capps Consultant chemical pathologist
Lipid Clinic, Princess Royal Hospital, Telford
TF6 6TF
1 NHS Executive. SMAC statement on use of statins. Wetherby,
West Yorkshire: Department of Health, 1997. (Executive
letter EL(97)41.)
2 103 experts. Use of statins: standing medical advisory
committee should reconsider advice to use Sheffield risk
table. BMJ 1997:315:1620. (letter.)
3 NHS Centre for Reviews and Dissemination. Cholesterol
and coronary heart disease. Effective Health Care Bull
1998;4.
4 Anonymous. Imperial Cancer Research Fund OXCHECK
Study Group. Effectiveness of health checks conducted by
nurses in primary care: results of the OXCHECK study.
BMJ 1996;310:1099›104.
5 Shepherd J. Identification of high risk groups and
comparison with other cardiovascular intervention trials.
Lancet 1996;348:1339›42.
Dilemmas exist in withdrawing
ventilation from dying children
Editor—We agree with Jonathan Gillis
about the guidelines of the Royal College of
Paediatrics and Child Health on withhold›
ing or withdrawing life saving treatment in
children.1 2 There is little doubt about the
need for such a document. Modern treat›
ment has made it possible to prolong life
beyond the point where continued treat›
ment is physiologically futile and the
benefits of living might be outweighed by
the physical and psychological cost of inten›
sive care. The document reinforces the stand
point that there should be no ethical
difference between withholding and with›
drawing treatment, but Gillis points out that
in practice there is an emotional difference.
His view is supported by our recent survey
of 73 consultants in paediatric intensive care
in the United Kingdom which documented
the uncertainty surrounding these issues.3
Fifty one per cent of respondents believed
there to be a moral difference between with›
holding and withdrawing ventilatory sup›
port, contrary to current published opinion.4
Our survey focused primarily on how
withdrawal was accomplished; 42% of
respondents preferred extubation to terminal
weaning of mechanical ventilation, with
nearly half (49%) using a higher dose of seda›
tive during withdrawal. Although the guide›
lines allow the use of sedative drugs in
increased dose during this process, the
primary intention should be to relieve
discomfort rather than hasten death. Nine
respondents (12%) continued paralytic
agents during extubation, presumably to
abolish the distress of agonal respiratory
efforts, but undeniably speeding the process
of death. The college document supports the
continuation of paralysis under these circum›
stances, yet some physicians would consider
this practice tantamount to euthanasia.5
In our own practice we recognise that
withdrawal should proceed swiftly with the
minimum distress to the child and family
and that under these circumstances it may
be appropriate to extubate dying children
under high dose analgesia and sedation.
However, it is not current policy in our unit
to continue neuromuscular paralysis during
the process of withdrawal.
Mark Hatherill Fellow in paediatric intensive care
Shane M Tibby Fellow in paediatric intensive care
Kim Sykes Resident in paediatric intensive care
Ian A Murdoch Director
Paediatric Intensive Care Unit, Guy’s Hospital,
London SE1 9RT
1 Gillis J. When lifesaving treatment in children is not the
answer. BMJ 1997;315:1246›7. (15 November.)
2 Royal College of Paediatrics and Child Health.Withholding
or withdrawing life saving treatment in children:a framework for
practice. London: RCPCH, 1997.
3 Hatherill M, Tibby SM, Williams C, Marsh MJ, Murdoch IA.
Withdrawal of ventilation from the dying child. Clin Inten›
sive Care 1997;8:222›7.
4 Task Force on Ethics of the Society of Critical Care Medi›
cine. Consensus report on the ethics of foregoing
life›sustaining treatments in the critically ill. Crit Care Med
1990;18:1435›9.
5 Sottile F. Managing dying patients and paralytic agents.
Chest 1995;108:887.
Prescribing patient information
leaflets may be better than
prescribing drugs
Editor—Greenhalgh and Gill highlight the
“disparate factors on the decision to
prescribe,” but they offer little advice in
terms of strategies to resist the pressure to
prescribe.1 They describe a study in which
22% of prescriptions were thought to be not
strictly indicated by the prescribing general
practitioner.2 Giving an information leaflet
on some of these occasions (for example, for
self limiting illnesses) may be an alternative
to a prescription and often more appropri›
ate. In addition, giving written information
reduces re›consultation rates for some
recurring conditions, which may also reduce
prescribing.3 4 This is apart from the many
other benefits to patients who receive
written information to complement the ver›
bal advice from their doctor.5
To “prescribe” a leaflet for most com›
mon conditions seen in general practice is
now routinely possible. Comprehensive
databases of patient leaflets are now a stand›
ard part of general practice computing. A
leaflet can be accessed quickly and can be
customised, personalised, and printed as
part of the consultation. Patient leaflets are
also being linked to clinical decision support
systems. For example, when accessing one of
the 240 clinical guidelines in PRODIGY (a
computerised prescribing decision support
system for general practitioners in the
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United Kingdom) the general practitioner is
offered the option of printing a leaflet to
give to the patient about his or her illness in
addition to any prescription options.
Printing and issuing a personalised
patient leaflet can be almost as quick as print›
ing a prescription. Further studies are
required to show the acceptability of this
alternative and in which situations their use is
most appropriate. Even a small shift towards
issuing a “PIL” (patient information leaflet)
instead of a prescription for pills will result in
considerable savings to the drug budget.
T Kenny* General practitioner
R Wilson* Research associate
I N Purves* Head of centre
Sowerby Centre for Health Informatics at
Newcastle, Newcastle University, Primary Care
Development Centre, Newcastle General Hospital,
Newcastle upon Tyne NE4 6BE
*The authors are part of the PRODIGY team. TK is
also editor of PILS, a widely used database of patient
leaflets.
1 Greenhalgh T, Gill P. Pressure to prescribe. BMJ 1997;
315:1482›3. (6 December.)
2 Britten N, Ukoumunne O. The influence of patients’ hopes
of receiving a prescription on doctors’ perceptions and the
decision to prescribe: a questionnaire survey. BMJ
1997;315:1506›10. (6 December.)
3 MacFarlane JT, Holmes WF, MacFarlane RM. Reducing
reconsultations for acute lower respiratory tract illness
with an information leaflet: a randomized controlled study
of patients in primary care. Br J Gen Pract 1997;47:719›22.
4 Roland M, Dixon M. Randomised controlled trial of an
educational booklet for patients presenting with back pain
in general practice. J R Coll Gen Pract 1989;39:244›6.
5 Collings CH, Pike LC, Binder AI, McClymont ME, Knight
ST. Value of written health information in the general
practice setting. Br J Gen Pract 1991;352:466›7.
Substitution of another opioid
for morphine
Opioid toxicity should be managed
initially by decreasing the opioid dose
Editor—We would like to clarify some
important points arising from Murray’s
letter about the substitution of another
opioid for morphine being of use in pain
control.1 The first is the description of pain
being “relatively resistant to morphine.” It is
more useful to think of responsiveness to
opioids as a continuum; the factors that gen›
erally decide the position on the continuum
are the side effects of opioids, particularly
sedation.2 Some pains, especially neuro›
pathic pain, require larger doses of opioids,
which consequently give rise to more
troublesome side effects and thus limit an
escalation of the dose and the achievement
of adequate analgesia. Opioid toxicity results
from an unfavourable balance between
analgesia and the side effects of opioids.
While alternative opioids may produce a
better outcome,3 the safest and most efficient
management of opioid toxicity is to reduce
the opioid dose in the first instance rather
than switch to an alternative opioid. This
approach commonly achieves the desired
balance between analgesia and side effects.4
Murray’s comment about ketamine (an
N›methyl D›aspartate (NMDA) antagonist)
in neuropathic pain is interesting. The
NMDA antagonists are promising drugs for
the treatment of pain syndromes with the
clinical phenomena of central “wind›up”
(allodynia, hyperalgesia, hyperpathia). The
opioid mechanism does, however, seem to
be crucial here also; NMDA antagonists
seem to renew the opioid responsiveness in
vitro and in the clinical situation.5
While alternative opioids to morphine,
and the NMDA antagonists, are important as
analgesics, we would reinforce a simple,
systematic approach to pain control as
outlined in the first paper in the ABC series
on palliative care. In particular, opioid toxicity
should be managed initially by decreasing the
opioid dose rather than automatically switch›
ing to an alternative opioid.
Marie T Fallon Marie Curie senior lecturer
Beaston Oncology Centre, Western Infirmary,
Glasgow
Bill O’Neill Science and research adviser
BMA, London WC1H 9JP
1 Murray P. Substitution of another opioid for morphine
may be useful for pain control. BMJ 1998;316:702›3.
(28 February.)
2 Fallon MT, Hanks GW. Opioid›resistant pain in cancer:
sense or nonsense. Pain Clin 1993;6:205›6.
3 Fallon M. Opioid rotation: does it have a role? Palliat Med
1997;11:177›8.
4 Hawley P, Forbes K, Hanks GW. Opioids, confusion and
opioid rotation. Palliat Med 1998;12:63›4.
5 Fallon MT, Welsh J. The role of ketamine in pain control.
Eur J Palliat Care 1996;3:143›6.
Methadone can be used to manage
neuropathic pain related to cancer
Editor—Murray fails to mention the poten›
tial that methadone has for managing neuro›
pathic pain related to cancer, advocating the
use of ketamine.1 Evidence is increasing that
hypersensitisation states characteristic of
neuropathic pain involve activation of the
N›methyl D›aspartate (NMDA) receptor.2
Activation of this receptor has a crucial role in
the development of tolerance to the analgesic
effects of morphine.
Treating such patients with drugs with
NMDA receptor antagonist properties may
attenuate this tolerance. The affinity of
methadone for the NMDA receptor is similar
to that of ketamine3; furthermore, like
morphine and unlike ketamine, methadone
has a high affinity for the ì receptor, where it
acts as a full agonist. There are thus theoreti›
cal advantages in using a ì opioid agonist that
also acts as a non›competitive NMDA
receptor antagonist—that is, methadone. This
has led us to apply revised guidelines for the
use of methadone in cancer pain with a
dominant neuropathic component.3
The renewed interest in methadone and
the emergence of new strong opioids (fenta›
nyl, hydromorphone, and oxycodone) on
the United Kingdom market may lead to
confusion among health professionals and
detract from the optimum use of morphine
in the management of chronic cancer pain.
Indications for the use of alternatives to
morphine require clarification.
In our opinion, there are two important
indications for choosing alternatives to mor›
phine. One of these is when, during
continuous use, intolerable central nervous
system side effects develop and reducing the
dose has no effect or leads to increased pain.
The second indication is when dose limiting
side effects of morphine occur, prohibiting
an increase in dose and giving rise to
inadequate analgesia (despite the use of
coanalgesics and techniques appropriate to
the pain syndrome).
The reason why opioid substitution is
successful in these cases remains unclear.
The development of severe central nervous
system side effects has been associated with
the accumulation of large amounts of the
morphine metabolite morphine›3›
glucuronide. This has central stimulatory
properties with a potency several hundred
times that of morphine,4 and thus a
reduction of side effects after the substitu›
tion of an opioid without known active
metabolites (for example, fentanyl or metha›
done) is explained. In some patients, pain
that is poorly responsive to morphine may
arise because of the development of
tolerance to morphine. If tolerance to side
effects does not develop to the same extent
as tolerance to analgesia the escalating dose
of morphine may reach a level at which the
side effects become dominant.5
M K Makin Specialist registrar in palliative medicine
J E Ellershaw Medical director
Marie Curie Centre Liverpool, Woolton, Liverpool
L25 8QA
1 Murray P. Substitution of another opioid for morphine
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(28 February.)
2 Ebert B, Anderson S, Krogsgaard›Larsen P. Ketomebi›
done, methadone and pethidine are non›competitive
N›methyl D›aspartate antagonists in the rat cortex and
spinal cord. Neurosci Lett 1995;187:165›8.
3 Morley JS, Makin MK. The use of methadone in cancer
pain poorly responsive to other opioids. Pain Rev 1998;
5:51›8.
4 Bartlett SE, Dodd PR, Smith MT. Pharmacology of
morphine and M3G at opioid, excitatory amino acid,
GABA and glycine binding sites. Pharmacol Toxicol 1994;
75:73›81.
5 Fallon M. Opioid rotation: does it have a role? Palliat Med
1997;11:177›8.
Consideration of short term
consequences of heavier babies
is important
Editor—I read with interest the paper by
Bonellie and Raab about the increase in
birth weight among babies born in Scotland
between 1980 and 1992.1 Various factors
were proposed as being responsible for this
increase including a reduction in the
proportion of induced births, lowered rates
of cigarette smoking, and improvements in
maternal diet and lifestyle.
During the same period we conducted a
prospective study on the predictability of
shoulder dystocia, an obstetric complication
that is potentially catastrophic for both
mother and baby, at the National Maternity
Hospital in Dublin.2 Our results confirmed
existing data that the incidence of shoulder
dystocia increases as birth weight increases.
The overall incidence of shoulder dystocia
was 0.6% (66/10 468) but the incidence
among babies weighing from 4 to 4.5 kg
was 1.9% (35/1790), and among those
weighing more than 4.5 kg was 5.8%
(23/395). While it was difficult to accurately
compare the incidence of shoulder dystocia
in 1992 with that from a decade or so
earlier, our impression was that the
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incidence was increasing due to an increase
in the number of heavier babies.
We therefore compared the incidence of
babies weighing > 4 kg and of babies weigh›
ing > 4.5 kg in 1979 and 1992. The
incidence of babies weighing > 4 kg in 1979
was 12.5% (1143/9159) compared with
19.4% (1220/6293) in 1992, and of babies
weighing > 4.5 kg was 2.9% (269/9159) in
1979 and 4% (252/6293) in 1992. This
occurred during a time when rates of
cigarette smoking and induction of labour
were essentially similar.
During labour heavier babies are associ›
ated with a higher incidence of dystocia.3
Apart from the problem of shoulder
dystocia, this trend towards a greater
number of heavier babies will undoubtedly
lead to increased obstetric intervention.
There has been a general increase in the
rates of caesarean section both in the United
Kingdom and Ireland in recent years. While
the reasons for this are multifactorial, the
increasing birth weight and the greater
number of heavier babies are certain to be
important factors. While it is interesting to
consider the long term implications of rising
birth weight on the pattern of adult disease,4
we should first consider the problems that
may arise in the shorter term.
Michael Geary Clinical research fellow
Department of Obstetrics and Gynaecology,
University College London Medical School,
London WC1E 6HX
1 Bonnellie SR, Raab GM. Why are babies getting heavier?
Comparison of Scottish births from 1980 to 1992. BMJ
1997;315:1205. (8 November.)
2 Geary M, McParland P, Johnson H, Stronge J. Shoulder
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1995;62:15›8.
3 Turner MJ, Rasmussen MJ, Boylan PC, McDonald D,
Stronge JM. The influence of birthweight on labor in nulli›
paras. Obstet Gynecol 1990;76:159›63.
4 Barker DJP, ed. Fetal and infant origins of adult disease.
London: BMJ Publishing, 1992.
Genetic counselling must be
non›directive
Editor—Minerva seems to hold the view
that the aim of genetic counselling for
parents who have a child with cystic fibrosis
is to prevent them having further affected
children.1 She reports that of 42 families, 24
had declined prenatal testing and eight had
accepted prenatal diagnosis but had decided
against termination. She concludes that
“part of the problem seems to have been
poor communication between the doctors
who should be providing the advice.”
I had always been under the impression
that counselling should be non›directive.
Minerva perhaps does not understand that
many parents do not want to undergo tests
that might lead on to the abortion of their
child; or even that many parents, having had
a positive test result, still feel able to value
their child’s life, whether or not there may be
a handicap.
Robert Aston Consultant in communicable disease
control
43 Churchgate, Bolton BL1 1JF
1 Minerva. BMJ 1998;316:240. (17 January.)
Private practice should mirror
the NHS
Fee structure for anaesthetists in private
practice needs overhaul
Editor—I agree with Machin’s statement that
“It is a point of principle that private practice
should mirror the NHS.”1 Equality between
consultants has been recognised with identi›
cal status and remuneration since the
inception of the NHS. The advent of day sur›
gery has resulted in the duties of consultant
surgeons and anaesthetists becoming identi›
cal with regard to preoperative assessment,
intraoperative management, and postopera›
tive care; if anything, the anaesthetist has
greater involvement on the day, as the
surgeon has already seen the patient in the
outpatient clinic. In private practice the
surgeon charges a fee for this consultation.
Many anaesthetists believe that the time
has come for a radical overhaul of the fee
structure in private practice, so that it
rewards appropriately the professional skills
of anaesthetists rather than reflecting values
of a bygone age. Can Machin give an assur›
ance that the BMA’s private practice
committee supports the basic principle of
private practice mirroring the NHS
throughout all private practice? Can he
explain why this principle of equality should
not apply to remuneration for similar
commitment in the independent sector?
R E Atkinson Chairman
Independent Practice Committee, Association of
Anaesthetists of Great Britain and Ireland, London
WC1B 3RA
1 Beecham L. BMA will seek GMC advice over BUPA
scheme. BMJ 1998;316:784. (7 March.)
Reply from chairman of BMA’s private
practice committee
Editor—The speech that I made in council
concerned the attempts made by BUPA to
influence consultant referrals by general
practitioners and hospital admissions by con›
sultants through the BUPA consultant “part›
nership” scheme. I was concerned that
patients should be treated in a similar fashion
in both the NHS and the private sector.
It would be foolhardy to give a
reassurance that the BMA’s private practice
committee supports the basic principle of
private practice mirroring the NHS
throughout all private practice, because the
two systems are so different that they cannot
be compared directly in many areas. Major
changes would have to be made to one or
both systems to enable us to achieve
anything approaching Atkinson’s require›
ment. The NHS is a salaried service with
additional benefits such as distinction
awards and pensions whereas the private
sector works on the basis of a fee for an item
of service, with the procedure determining
the fee, irrespective of whether it is done on
a day case or inpatient basis. Would
Atkinson be happy with a salaried private
sector? Any threat to employ consultants
in private hospitals would be greatest to
anaesthetists, who provide for all surgical
specialties.
Earnings in the private sector vary,
depending enormously on such factors as
situation, specialty, and reputation. The
expenses of different specialist groups are
different—anaesthetists do not usually have
consulting rooms or secretaries. The value of
various activities is different—consultations
give rise to a lower rate than procedures. Sur›
geons spend over half of their “private” time
consulting or visiting patients after opera›
tions, and for this activity there is no specific
payment. I do not believe that it would ever be
possible to achieve equality between special›
ties but the question of equity between
specialties is one that will be addressed by my
committee, and as a member Atkinson is well
placed to influence the deliberations.
Derek G Machin Chairman
Private Practice Committee,
BMA, London WC1H 9HP
Only minority of doctors
supported idea of state funded
health service in 1945
Editor—Macpherson has given a valuable
account of how the NHS was finally launched
50 years ago after nearly three years of bitter
negotiations, but at one point he tries too
hard to be tactful about the attitude of most
doctors at the time.1 It would be less than
honest not to challenge his statement that “in
1945 most doctors probably supported the
principle of a state funded health service.”
The evidence is all the other way. Throughout
the years 1945›8 it was quite clearly a minor›
ity, not a majority, of the medical profession
that supported this principle.
As so often, it was not so much what was
proposed (broadly supported by all political
parties and by the Lancet) that aroused such
an outcry but intense fear of where it might
lead. Eight of us, medical students at the
time, signed a letter which started, “We are
puzzled by the refusal of an overwhelming
majority of the medical profession to serve
in the National Health Service.”2 We were
not popular.
In this—and in nearly every similar
confrontation since—I have been struck by
the way in which so many of the most hard
working and the most caring doctors
(whether in hospital or in general practice)
have been among the most politically
inflexible. In the early part of the century
Lloyd George, who had great difficulty
persuading the profession to accept even the
very limited financial help that preceded the
NHS, found doctors “unruly and unreason›
able.” Many years later Kenneth Clark, who
was equally experienced at negotiating with
all sections of the community, said that he had
never encountered any group so difficult to
talk to as doctors. Why should this be?
Thurstan Brewin Consultant in clinical oncology
(retired)
Flat 82, Pegasus Grange, Whitehouse Road, Oxford
OX1 4QQ
1 Macpherson G. 1948: a turbulent gestation for the NHS.
BMJ 1998;316:6. (3 January.)
2 Brewin TB, Ellis FG, Glenn RW, McGuire ET, Nicholson
RG, Salmon AJ, et al. National Health Service. Guy’s
Hospital Gazette 1948;62:76.
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